company background image
XXII

22nd Century Group NasdaqCM:XXII Stock Report

Last Price

US$1.11

Market Cap

US$239.0m

7D

-8.3%

1Y

-45.6%

Updated

29 Jan, 2023

Data

Company Financials +

22nd Century Group, Inc.

NasdaqCM:XXII Stock Report

Mkt Cap: US$239.0m

XXII Stock Overview

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries.

XXII fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

22nd Century Group, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 22nd Century Group
Historical stock prices
Current Share PriceUS$1.11
52 Week HighUS$2.71
52 Week LowUS$0.82
Beta1.84
1 Month Change20.59%
3 Month Change-15.27%
1 Year Change-45.59%
3 Year Change19.77%
5 Year Change-59.34%
Change since IPO-14.62%

Recent News & Updates

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13
Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Recent updates

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13
Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

22nd Century Group (NASDAQ:XXII) Has Debt But No Earnings; Should You Worry?

Sep 02
22nd Century Group (NASDAQ:XXII) Has Debt But No Earnings; Should You Worry?

Will 22nd Century Group (NASDAQ:XXII) Spend Its Cash Wisely?

May 10
Will 22nd Century Group (NASDAQ:XXII) Spend Its Cash Wisely?

Is 22nd Century Group (NASDAQ:XXII) A Risky Investment?

Nov 23
Is 22nd Century Group (NASDAQ:XXII) A Risky Investment?

We Think 22nd Century Group (NYSEMKT:XXII) Can Afford To Drive Business Growth

Mar 23
We Think 22nd Century Group (NYSEMKT:XXII) Can Afford To Drive Business Growth

Introducing 22nd Century Group (NYSEMKT:XXII), The Stock That Zoomed 164% In The Last Year

Jan 27
Introducing 22nd Century Group (NYSEMKT:XXII), The Stock That Zoomed 164% In The Last Year

Is 22nd Century Group (NYSEMKT:XXII) A Risky Investment?

Dec 01
Is 22nd Century Group (NYSEMKT:XXII) A Risky Investment?

Shareholder Returns

XXIIUS TobaccoUS Market
7D-8.3%-4.9%2.8%
1Y-45.6%-16.0%-9.2%

Return vs Industry: XXII underperformed the US Tobacco industry which returned -16% over the past year.

Return vs Market: XXII underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is XXII's price volatile compared to industry and market?
XXII volatility
XXII Average Weekly Movement12.1%
Tobacco Industry Average Movement13.0%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: XXII's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199876Jim Mishhttps://www.xxiicentury.com

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.

22nd Century Group, Inc. Fundamentals Summary

How do 22nd Century Group's earnings and revenue compare to its market cap?
XXII fundamental statistics
Market CapUS$238.98m
Earnings (TTM)-US$47.48m
Revenue (TTM)US$49.14m

4.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XXII income statement (TTM)
RevenueUS$49.14m
Cost of RevenueUS$45.53m
Gross ProfitUS$3.61m
Other ExpensesUS$51.09m
Earnings-US$47.48m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin7.35%
Net Profit Margin-96.62%
Debt/Equity Ratio5.0%

How did XXII perform over the long term?

See historical performance and comparison